undamentalytics Newsletter
Sign in

Pacira Biosciences, Inc. income statement

In fiscal 2025, Pacira Biosciences, Inc. reported revenue of $726m, up 3.6% on the year before, operating income of $19.2m (a 2.6% margin) and net income of $7.0m, or $0.16 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1515163986198249276287337421430542667675701726746
Cost of revenue121217325577721108887107117140199185170150155
Gross profit32−1731120177166199250314312401468490531577591
Research and development26191510221929465756725956857682117122
Selling, general and administrative56204663107139153161177201194199255269294369379
Operating income−29−23−39−49−53−59−32−25161046906088−731920
Interest expense2452788718222426324020171715
Income before tax——−43−52−64−142−38−42−0−1120561362−631718
Income tax——00−0000000−12514−32036103
Net income−32−27−43−52−64−142−38−43−0−11146421642−100715
Diluted EPS−$55.32−$47.29−$2.64−$1.72−$1.93−$0.39$0.04−$1.02−$1.07−$0.01−$0.27$3.33$0.92$0.34$0.89−$2.15$0.16$0.35
Diluted shares (average)——16m30m33m35m41m37m40m41m42m44m46m47m52m46m45m42m
EBITDA−24−19−35−44−48521−19−11293066118152163511076

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AMPH vs PCRXCORT vs PCRXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pacira Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pacira Biosciences, Inc.